Global Bipolar Disorder Therapeutics Market 2024-2028

The bipolar disorder therapeutics market is forecasted to grow by USD 787.02 mn during 2023-2028, accelerating at a CAGR of 2.68% during the forecast period. The report on the bipolar disorder therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing incidence of bipolar disorder, advancements in drug development, and increasing holistic treatment approaches.

Market Scope
Base Year	2023
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	1.96%
CAGR	2.68%
Incremental Value	$787.02mn

Technavio's bipolar disorder therapeutics market is segmented as below:

By Drug Class

Antipsychotics
Mood stabilizers
Antidepressants
Others

By Distribution Channel

Hospital pharmacies
Retail pharmacies
Online pharmacies

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the increased prevalence of personalized treatment due to advances in genetics and neuroscience as one of the prime reasons driving the bipolar disorder therapeutics market growth during the next few years. Also, increasing global adoption of mental health services and increasing use of telemedicine and digital health tools will lead to sizable demand in the market.

The report on the bipolar disorder therapeutics market covers the following areas:

Bipolar disorder therapeutics market sizing
Bipolar disorder therapeutics market forecast
Bipolar disorder therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading bipolar disorder therapeutics market vendors that include AbbVie Inc., Amneal Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Eli Lilly and Co., Gedeon Richter Plc, GlaxoSmithKline Plc, H Lundbeck AS, Intra-Cellular Therapies Inc., Mallinckrodt Plc, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sumitomo Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., The London Psychiatry Centre, Wockhardt Ltd., and Zydus Lifesciences Ltd.. Also, the bipolar disorder therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR76803

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global bipolar disorder therapeutics market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global bipolar disorder therapeutics market 2018 - 2022 ($ million)
4.2 Drug Class Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
4.3 Distribution Channel Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Drug Class

6.1 Market segments
Exhibit 30: Chart on Drug Class - Market share 2023-2028 (%)
Exhibit 31: Data Table on Drug Class - Market share 2023-2028 (%)
6.2 Comparison by Drug Class
Exhibit 32: Chart on Comparison by Drug Class
Exhibit 33: Data Table on Comparison by Drug Class
6.3 Antipsychotics - Market size and forecast 2023-2028
Exhibit 34: Chart on Antipsychotics - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Data Table on Antipsychotics - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Chart on Antipsychotics - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Antipsychotics - Year-over-year growth 2023-2028 (%)
6.4 Mood stabilizers - Market size and forecast 2023-2028
Exhibit 38: Chart on Mood stabilizers - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Data Table on Mood stabilizers - Market size and forecast 2023-2028 ($ million)
Exhibit 40: Chart on Mood stabilizers - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Mood stabilizers - Year-over-year growth 2023-2028 (%)
6.5 Antidepressants - Market size and forecast 2023-2028
Exhibit 42: Chart on Antidepressants - Market size and forecast 2023-2028 ($ million)
Exhibit 43: Data Table on Antidepressants - Market size and forecast 2023-2028 ($ million)
Exhibit 44: Chart on Antidepressants - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Antidepressants - Year-over-year growth 2023-2028 (%)
6.6 Others - Market size and forecast 2023-2028
Exhibit 46: Chart on Others - Market size and forecast 2023-2028 ($ million)
Exhibit 47: Data Table on Others - Market size and forecast 2023-2028 ($ million)
Exhibit 48: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 49: Data Table on Others - Year-over-year growth 2023-2028 (%)
6.7 Market opportunity by Drug Class
Exhibit 50: Market opportunity by Drug Class ($ million)
Exhibit 51: Data Table on Market opportunity by Drug Class ($ million)

7 Market Segmentation by Distribution Channel

7.1 Market segments
Exhibit 52: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 53: Data Table on Distribution Channel - Market share 2023-2028 (%)
7.2 Comparison by Distribution Channel
Exhibit 54: Chart on Comparison by Distribution Channel
Exhibit 55: Data Table on Comparison by Distribution Channel
7.3 Hospital pharmacies - Market size and forecast 2023-2028
Exhibit 56: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
7.4 Retail pharmacies - Market size and forecast 2023-2028
Exhibit 60: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 61: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 62: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
7.5 Online pharmacies - Market size and forecast 2023-2028
Exhibit 64: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 65: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 66: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 67: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Distribution Channel
Exhibit 68: Market opportunity by Distribution Channel ($ million)
Exhibit 69: Data Table on Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 71: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 72: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 73: Chart on Geographic comparison
Exhibit 74: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Germany - Market size and forecast 2023-2028
Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.9 China - Market size and forecast 2023-2028
Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
9.10 Canada - Market size and forecast 2023-2028
Exhibit 103: Chart on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 104: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 105: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on Canada - Year-over-year growth 2023-2028 (%)
9.11 UK - Market size and forecast 2023-2028
Exhibit 107: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 108: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 109: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 110: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 111: Market opportunity By Geographical Landscape ($ million)
Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 113: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 115: Overview on factors of disruption
11.4 Industry risks
Exhibit 116: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 117: Vendors covered
12.2 Market positioning of vendors
Exhibit 118: Matrix on vendor position and classification
12.3 AbbVie Inc.
Exhibit 119: AbbVie Inc. - Overview
Exhibit 120: AbbVie Inc. - Product / Service
Exhibit 121: AbbVie Inc. - Key news
Exhibit 122: AbbVie Inc. - Key offerings
12.4 Astellas Pharma Inc.
Exhibit 123: Astellas Pharma Inc. - Overview
Exhibit 124: Astellas Pharma Inc. - Product / Service
Exhibit 125: Astellas Pharma Inc. - Key news
Exhibit 126: Astellas Pharma Inc. - Key offerings
12.5 AstraZeneca Plc
Exhibit 127: AstraZeneca Plc - Overview
Exhibit 128: AstraZeneca Plc - Product / Service
Exhibit 129: AstraZeneca Plc - Key news
Exhibit 130: AstraZeneca Plc - Key offerings
12.6 Bristol Myers Squibb Co.
Exhibit 131: Bristol Myers Squibb Co. - Overview
Exhibit 132: Bristol Myers Squibb Co. - Product / Service
Exhibit 133: Bristol Myers Squibb Co. - Key news
Exhibit 134: Bristol Myers Squibb Co. - Key offerings
12.7 Eli Lilly and Co.
Exhibit 135: Eli Lilly and Co. - Overview
Exhibit 136: Eli Lilly and Co. - Product / Service
Exhibit 137: Eli Lilly and Co. - Key news
Exhibit 138: Eli Lilly and Co. - Key offerings
12.8 Gedeon Richter Plc
Exhibit 139: Gedeon Richter Plc - Overview
Exhibit 140: Gedeon Richter Plc - Business segments
Exhibit 141: Gedeon Richter Plc - Key news
Exhibit 142: Gedeon Richter Plc - Key offerings
Exhibit 143: Gedeon Richter Plc - Segment focus
12.9 GlaxoSmithKline Plc
Exhibit 144: GlaxoSmithKline Plc - Overview
Exhibit 145: GlaxoSmithKline Plc - Business segments
Exhibit 146: GlaxoSmithKline Plc - Key news
Exhibit 147: GlaxoSmithKline Plc - Key offerings
Exhibit 148: GlaxoSmithKline Plc - Segment focus
12.10 H Lundbeck AS
Exhibit 149: H Lundbeck AS - Overview
Exhibit 150: H Lundbeck AS - Product / Service
Exhibit 151: H Lundbeck AS - Key offerings
12.11 Mallinckrodt Plc
Exhibit 152: Mallinckrodt Plc - Overview
Exhibit 153: Mallinckrodt Plc - Business segments
Exhibit 154: Mallinckrodt Plc - Key offerings
Exhibit 155: Mallinckrodt Plc - Segment focus
12.12 Novartis AG
Exhibit 156: Novartis AG - Overview
Exhibit 157: Novartis AG - Business segments
Exhibit 158: Novartis AG - Key offerings
Exhibit 159: Novartis AG - Segment focus
12.13 Otsuka Holdings Co. Ltd.
Exhibit 160: Otsuka Holdings Co. Ltd. - Overview
Exhibit 161: Otsuka Holdings Co. Ltd. - Business segments
Exhibit 162: Otsuka Holdings Co. Ltd. - Key offerings
Exhibit 163: Otsuka Holdings Co. Ltd. - Segment focus
12.14 Pfizer Inc.
Exhibit 164: Pfizer Inc. - Overview
Exhibit 165: Pfizer Inc. - Product / Service
Exhibit 166: Pfizer Inc. - Key news
Exhibit 167: Pfizer Inc. - Key offerings
12.15 Sumitomo Pharma Co. Ltd.
Exhibit 168: Sumitomo Pharma Co. Ltd. - Overview
Exhibit 169: Sumitomo Pharma Co. Ltd. - Business segments
Exhibit 170: Sumitomo Pharma Co. Ltd. - Key offerings
Exhibit 171: Sumitomo Pharma Co. Ltd. - Segment focus
12.16 Sun Pharmaceutical Industries Ltd.
Exhibit 172: Sun Pharmaceutical Industries Ltd. - Overview
Exhibit 173: Sun Pharmaceutical Industries Ltd. - Product / Service
Exhibit 174: Sun Pharmaceutical Industries Ltd. - Key offerings
12.17 The London Psychiatry Centre
Exhibit 175: The London Psychiatry Centre - Overview
Exhibit 176: The London Psychiatry Centre - Product / Service
Exhibit 177: The London Psychiatry Centre - Key offerings

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 178: Inclusions checklist
Exhibit 179: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 180: Currency conversion rates for US$
13.4 Research methodology
Exhibit 181: Research methodology
Exhibit 182: Validation techniques employed for market sizing
Exhibit 183: Information sources
13.5 List of abbreviations
Exhibit 184: List of abbreviations